PDF herunterladen
Geburtshilfe Frauenheilkd 2006; 66(9): 841-851
DOI: 10.1055/s-2006-924283
Übersicht

Georg Thieme Verlag KG Stuttgart · New York

Metabolismus und Mammakarzinom

Breast Cancer and MetabolismG. H. Pfeiler1 , C. Lattrich1 , C. Schambeck2 , T. Langmann2 , O. Treeck1 , O. Ortmann1
  • 1Klinik für Frauenheilkunde und Geburtshilfe, Caritas Krankenhaus St. Josef, Universität Regensburg, Regensburg
  • 2Institut für Klinische Chemie und Laboratoriumsmedizin, Universität Regensburg, Regensburg
Weitere Informationen

Publikationsverlauf

Eingang Manuskript: 2.3.2006 Eingang revidiertes Manuskript: 7.4.2006

Akzeptiert: 10.5.2006

Publikationsdatum:
12. September 2006 (online)

Auch verfügbar auf
    Lizenzen und Reprints

Zusammenfassung

In den letzten Jahren hat der Zusammenhang zwischen metabolischen Störungen und dem Mammakarzinomrisiko zunehmendes Interesse gewonnen. Die Adipositas ist mit einem gesteigerten Brustkrebsrisiko assoziiert. Die Zunahme an Fettgewebe führt zu vermehrter extraglandulärer Östrogenbiosynthese, kann in erhöhten Serumspiegeln freier Fettsäuren (FFA) resultieren und zeigt einen starken Zusammenhang mit Insulinresistenz und somit Hyperinsulinämie. Östrogene, FFA und Insulin fördern das Wachstum von Brustkrebszellen und erhöhte Plasmaspiegel konnten in Beobachtungsstudien positiv mit dem Mammakarzinomrisiko korreliert werden. Adipozyten sezernieren zudem Adipokine, wie Adiponectin, Leptin, TNFα und IL-6, die das Wachstum von Brustkrebszellen auf unterschiedliche Weise beeinflussen können. Die vorliegende Übersichtsarbeit fasst den derzeitigen Kenntnisstand zum Zusammenhang zwischen Metabolismus und dem Mammakarzinomrisiko zusammen.

Abstract

Metabolic disorders are known to affect the risk for breast cancer. Obesity affects the risk and prognosis of different kinds of cancers, including breast cancer. Metabolic changes, such as increased estrogen biosynthesis, elevated serum free fatty acids (FFA), or hyperinsulinemia, associated with the metabolic syndrome are considered to be responsible for the effects of obesity on breast cancer. Furthermore, white adipose tissue secretes a wide range of biologically active peptides, including adiponectin, leptin, TNFα and IL-6. These adipocytokines have been shown to be involved in the development and progression of breast cancer. The focus of this review is to summarize the current knowledge on metabolic disorders as risk factors for breast cancer.

Schlüsselwörter

Mammakarzinom - Lipidmetabolismus - Diabetes mellitus Typ 2 - Adipozytokine - Adipositas

Key words

Breast cancer - lipid metabolism - type 2 diabetes mellitus - adipocytokines - obesity

Literatur

  • 1 Parkin D M. International variation.  Oncogene. 2004;  23 6329-6340
    CrossrefPubMedGoogle Scholar
  • 2 Bray F, Sankila R, Ferlay J, Parkin D M. Estimates of cancer incidence and mortality in Europe in 1995.  Eur J Cancer. 2002;  38 99-166
    CrossrefPubMedGoogle Scholar
  • 3 Key T J, Pike M C. The role of oestrogens and progestagens in the epidemiology and prevention of breast cancer.  Eur J Cancer Clin Oncol. 1988;  24 29-43
    CrossrefPubMedGoogle Scholar
  • 4 Dao T L. The role of ovarian steroid hormones in mammary carcinogenesis. Pike MC, Siiteri PK, Welsch CW Hormones and Breast Cancer. Banbury Report No. 8. Cold Spring Harbor (NY); Cold Spring Harbor Laboratory 1981: 281-295
    Google Scholar
  • 5 Ackerman G E, Smith M E, Mendelson C R, MacDonald P C, Simpson E R. Aromatization of androstenedione by human adipose tissue stromal cells in monolayer culture.  J Clin Endocrinol Metab. 1981;  53 412-417
    PubMedGoogle Scholar
  • 6 Miller W R, Forrest A P. Oestradiol synthesis by a human breast carcinoma.  Lancet. 1974;  2 866-868
    PubMedGoogle Scholar
  • 7 De Waard F, Baanders-Vanhalewijn E A, Huizinga J. The bimodal age distribution of patients with mammary carcinoma; evidence for the existence of 2 types of human breast cancer.  Cancer. 1964;  17 141-151
    CrossrefPubMedGoogle Scholar
  • 8 Bruning P F, Bonfrer J M, Hart A A, van Noord P A, van der Hoeven H, Collette H J, Battermann J J, de Jong-Bakker M, Nooijen W J, de Waard F. Body measurements, estrogen availability and the risk of human breast cancer: a case-control study.  Int J Cancer. 1992;  51 14-19
    PubMedGoogle Scholar
  • 9 Friedmann J M. Obesity in the new millennium.  Nature. 2000;  404 632-634
    PubMedGoogle Scholar
  • 10 Hu E, Liang P, Spiegelman B M. AdipoQ is a novel adipose-specific gene dysregulated in obesity.  J Biol Chem. 1996;  271 10697-10703
    CrossrefPubMedGoogle Scholar
  • 11 Maeda K, Okubo K, Shimomura I, Funahashi T, Matsuzawa Y, Matsubara K. cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1).  Biochem Biophys Res Commun. 1996;  221 286-289
    CrossrefPubMedGoogle Scholar
  • 12 Weisberg S P, McCann D, Desai M, Rosenbaum M, Leibel R L, Ferrante Jr A W. Obesity is associated with macrophage accumulation in adipose tissue.  J Clin Invest. 2003;  112 1796-1808
    CrossrefPubMedGoogle Scholar
  • 13 Kern P A, Ranganathan S, Li C, Wood L, Ranganathan G. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance.  Am J Physiol Endocrinol Metab. 2001;  280 E745-E751
    CrossrefPubMedGoogle Scholar
  • 14 Green A, Hougaard P. Epidemiological studies of diabetes mellitus in Denmark: 5. Mortality and causes of death among insulin-treated diabetic patients.  Diabetologia. 1984;  26 190-194
    PubMedGoogle Scholar
  • 15 Yancik R, Wesley M N, Ries L A, Havlik R J, Edwards B K, Yates J W. Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older.  JAMA. 2001;  285 885-892
    CrossrefPubMedGoogle Scholar
  • 16 Michels K B, Solomon C G, Hu F B, Rosner B A, Hankinson S E, Colditz G A, Manson J E. Nurses' Health Study . Type 2 diabetes and subsequent incidence of breast cancer in the Nurses' Health Study.  Diabetes Care. 2003;  26 1752-1758
    CrossrefPubMedGoogle Scholar
  • 17 Calle E E, Rodriguez C, Walker-Thurmond K, Thun M J. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults.  N Engl J Med. 2003;  348 1625-1638
    CrossrefPubMedGoogle Scholar
  • 18 Carroll K K. Obesity as a risk factor for certain types of cancer.  Lipids. 1998;  33 1055-1059
    PubMedGoogle Scholar
  • 19 Bergstrom A, Pisani P, Tenet V, Wolk A, Adami H O. Overweight as an avoidable cause of cancer in Europe.  Int J Cancer. 2001;  91 421-430
    CrossrefPubMedGoogle Scholar
  • 20 Peto J. Cancer epidemiology in the last century and the next decade.  Nature. 2001;  411 390-395
    CrossrefPubMedGoogle Scholar
  • 21 Michaud D S, Giovannucci E, Willett W C, Colditz G A, Stampfer M J, Fuchs C S. Physical activity, obesity, height, and the risk of pancreatic cancer.  JAMA. 2001;  286 921-929
    CrossrefPubMedGoogle Scholar
  • 22 Wolk A, Gridley G, Svensson M, Nyren O, McLaughlin J K, Fraumeni J F, Adam H O. A prospective study of obesity and cancer risk (Sweden).  Cancer Causes Control. 2001;  12 13-21
    CrossrefPubMedGoogle Scholar
  • 23 Moller H, Mellemgaard A, Lindvig K, Olsen J H. Obesity and cancer risk: a Danish record-linkage study.  Eur J Cancer. 1994;  30 A 344-350
    CrossrefPubMedGoogle Scholar
  • 24 IARC Working Group on the Evaluation of Cancer-Preventive Agents .Weight Control and Physical Activity, IARC Handbooks of Cancer Prevention, Volume 6. Lyon, France; IARC 2002
    Google Scholar
  • 25 van den Brandt P A, Spiegelman D, Yaun S S, Adami H O, Beeson L, Folsom A R, Fraser G, Goldbohm R A, Graham S, Kushi L, Marshall J R, Miller A B, Rohan T, Smith-Warner S A, Speizer F E, Willett W C, Wolk A, Hunter D J. Pooled analysis of prospective cohort studies on height, weight, and breast cancer risk.  Am J Epidemiol. 2000;  152 514-527
    CrossrefPubMedGoogle Scholar
  • 26 Paffenbarger Jr R S, Kampert J B, Chang H G. Characteristics that predict risk of breast cancer before and after the menopause.  Am J Epidemiol. 1980;  112 258-268
    PubMedGoogle Scholar
  • 27 Swanson C A, Coates R J, Schoenberg J B, Malone K E, Gammon M D, Stanford J L, Shorr I J, Potischman N A, Brinton L A. Body size and breast cancer risk among women under age 45 years.  Am J Epidemiol. 1996;  143 698-706
    PubMedGoogle Scholar
  • 28 Franceschi S, Favero A, La Vecchia C, Baron A E, Negri E, Dal Maso L, Giacosa A, Montella M, Conti E, Amadori D. Body size indices and breast cancer risk before and after menopause.  Int J Cancer. 1996;  67 181-186
    CrossrefPubMedGoogle Scholar
  • 29 Ursin G, Longnecker M P, Haile R W, Greenland S. A meta-analysis of body mass index and risk of premenopausal breast cancer.  Epidemiology. 1995;  6 137-141
    PubMedGoogle Scholar
  • 30 Potischman N, Swanson C A, Siiteri P, Hoover R N. Reversal of relation between body mass and endogenous estrogen concentrations with menopausal status.  J Natl Cancer Inst. 1996;  88 756-758
    PubMedGoogle Scholar
  • 31 Lahmann P H, Schulz M, Hoffmann K, Boeing H, Tjonneland A, Olsen A, Overvad K, Key T J, Allen N E, Khaw K T, Bingham S, Berglund G, Wirfalt E, Berrino F, Krogh V, Trichopoulou A, Lagiou P, Trichopoulos D, Kaaks R, Riboli E. Long-term weight change and breast cancer risk: the European prospective investigation into cancer and nutrition (EPIC).  Br J Cancer. 2005;  93 582-589
    CrossrefPubMedGoogle Scholar
  • 32 Chang S, Buzdar A U, Hursting S D. Inflammatory breast cancer and body mass index.  J Clin Oncol. 1998;  16 3731-3735
    PubMedGoogle Scholar
  • 33 Harvie M, Hooper L, Howell A H. Central obesity and breast cancer risk: a systematic review.  Obes Rev. 2003;  4 157-173
    CrossrefPubMedGoogle Scholar
  • 34 Mannisto S, Pietinen P, Pyy M, Palmgren J, Eskelinen M, Uusitupa M. Body-size indicators and risk of breast cancer according to menopause and estrogen-receptor status.  Int J Cancer. 1996;  68 8-13
    CrossrefPubMedGoogle Scholar
  • 35 Collaborative Group on Hormonal Factors in Breast Cancer . Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52705 women with breast cancer and 108411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer.  Lancet. 1997;  350 1047-1059
    CrossrefPubMedGoogle Scholar
  • 36 Petrelli J M, Calle E E, Rodriguez C, Thun M J. Body mass index, height, and postmenopausal breast cancer mortality in a prospective cohort of US women.  Cancer Causes Control. 2002;  13 325-332
    CrossrefPubMedGoogle Scholar
  • 37 Feigelson H S, Jonas C R, Teras L R, Thun M J, Calle E E. Weight gain, body mass index, hormone replacement therapy, and postmenopausal breast cancer in a large prospective study.  Cancer Epidemiol Biomarkers Prev. 2004;  13 220-224
    CrossrefPubMedGoogle Scholar
  • 38 Schapira D V, Kumar N B, Lyman G H. Estimate of breast cancer risk reduction with weight loss.  Cancer. 1991;  67 2622-2625
    CrossrefPubMedGoogle Scholar
  • 39 Evans R M. The steroid and thyroid hormone receptor superfamily.  Science. 1988;  240 889-895
    CrossrefPubMedGoogle Scholar
  • 40 Klotz D M, Hewitt S C, Ciana P, Raviscioni M, Lindzey J K, Foley J, Maggi A, DiAugustine R P, Korach K S. Requirement of estrogen receptor-alpha in insulin-like growth factor-1 (IGF‐1)-induced uterine responses and in vivo evidence for IGF‐1/estrogen receptor cross-talk.  J Biol Chem. 2002;  277 8531-8537
    CrossrefPubMedGoogle Scholar
  • 41 Macaluso M, Cinti C, Russo G, Russo A, Giordano A. pRb2/p 130-E2F4/5-HDAC1-SUV39H1-p 300 and pRb2/p 130-E2F4/5-HDAC1-SUV39H1-DNMT1 multimolecular complexes mediate the transcription of estrogen receptor-alpha in breast cancer.  Oncogene. 2003;  22 3511-3517
    CrossrefPubMedGoogle Scholar
  • 42 Henderson B E, Ross R, Bernstein L. Estrogens as a cause of human cancer: the Richard and Hinda Rosenthal Foundation award lecture.  Cancer Res. 1988;  48 246-253
    PubMedGoogle Scholar
  • 43 Feigelson H S, Ross R K, Yu M C, Coetzee G A, Reichardt J K, Henderson B E. Genetic susceptibility to cancer from exogenous and endogenous exposures.  J Cell Biochem Suppl . 1996;  25 15-22
    PubMedGoogle Scholar
  • 44 Foster J S, Wimalasena J. Estrogen regulates activity of cyclin-dependent kinases and retinoblastoma protein phosphorylation in breast cancer cells.  Mol Endocrinol. 1996;  10 488-498
    CrossrefPubMedGoogle Scholar
  • 45 Prall O W, Sarcevic B, Musgrove E A, Watts C K, Sutherland R L. Estrogen-induced activation of Cdk4 and Cdk2 during G1-S phase progression is accompanied by increased cyclin D1 expression and decreased cyclin-dependent kinase inhibitor association with cyclin E-Cdk2.  J Biol Chem. 1997;  272 10882-10894
    CrossrefPubMedGoogle Scholar
  • 46 Altucci L, Addeo R, Cicatiello L, Dauvois S, Parker M G, Truss M, Beato M, Sica V, Bresciani F, Weisz A. 17beta-Estradiol induces cyclin D1 gene transcription, p 36D1-p 34cdk4 complex activation and p 105Rb phosphorylation during mitogenic stimulation of G(1)-arrested human breast cancer cells.  Oncogene. 1996;  12 2315-2324
    PubMedGoogle Scholar
  • 47 Planas-Silva M D, Weinberg R A. Estrogen-dependent cyclin E-cdk2 activation through p 21 redistribution.  Mol Cell Biol. 1997;  17 4059-4069
    PubMedGoogle Scholar
  • 48 Lupulescu A. Estrogen use and cancer incidence: a review.  Cancer Invest. 1995;  13 287-295
    PubMedGoogle Scholar
  • 49 Pike M C, Spicer D V, Dahmoush L, Press M F. Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk.  Epidemiol Rev. 1993;  15 17-35
    PubMedGoogle Scholar
  • 50 Rosner B, Colditz G A. Nurses' health study: log-incidence mathematical model of breast cancer incidence.  J Natl Cancer Inst. 1996;  88 359-364
    PubMedGoogle Scholar
  • 51 Clemons M, Goss P. Estrogen and the risk of breast cancer.  N Engl J Med. 2001;  344 276-285
    CrossrefPubMedGoogle Scholar
  • 52 Bonney R C, Reed M J, Davidson K, Beranek P A, James V H. The relationship between 17 beta-hydroxysteroid dehydrogenase activity and oestrogen concentrations in human breast tumours and in normal breast tissue.  Clin Endocrinol (Oxf). 1983;  19 727-739
    PubMedGoogle Scholar
  • 53 Blankenstein M A, Maitimu-Smeele I, Donker G H, Daroszewski J, Milewicz A, Thijssen J H. On the significance of in situ production of oestrogens in human breast cancer tissue.  J Steroid Biochem Mol Biol. 1992;  41 891-896
    CrossrefPubMedGoogle Scholar
  • 54 Abul-Hajj Y J, Iverson R, Kiang D T. Aromatization of androgens by human breast cancer.  Steroids. 1979;  33 205-222
    CrossrefPubMedGoogle Scholar
  • 55 Lipton A, Santner S J, Santen R J, Harvey H A, Feil P D, White-Hershey D, Bartholomew M J, Antle C E. Aromatase activity in primary and metastatic human breast cancer.  Cancer. 1987;  59 779-782
    CrossrefPubMedGoogle Scholar
  • 56 Dao T L, Hayes C, Libby P R. Steroid sulfatase activities in human breast tumors.  Proc Soc Exp Biol Med. 1974;  146 381-384
    PubMedGoogle Scholar
  • 57 Pasqualini J R, Gelly C, Lecerf F. Estrogen sulfates: biological and ultrastructural responses and metabolism in MCF‐7 human breast cancer cells.  Breast Cancer Res Treat. 1986;  8 233-240
    CrossrefPubMedGoogle Scholar
  • 58 Pasqualini J R, Gelly C, Nguyen B L, Vella C. Importance of estrogen sulfates in breast cancer.  J Steroid Biochem. 1989;  34 155-163
    CrossrefPubMedGoogle Scholar
  • 59 Pasqualini J R, Chetrite G, Blacker C, Feinstein M C, Delalonde L, Talbi M, Maloche C. Concentrations of estrone, estradiol, and estrone sulfate and evaluation of sulfatase and aromatase activities in pre- and postmenopausal breast cancer patients.  J Clin Endocrinol Metab. 1996;  81 1460-1464
    CrossrefPubMedGoogle Scholar
  • 60 Loriaux D L, Ruder H J, Lipsett M B. The measurement of estrone sulfate in plasma.  Steroids. 1971;  18 463-472
    CrossrefPubMedGoogle Scholar
  • 61 Pasqualini J R, Gelly C, Lecerf F. Biological effects and morphological responses to estriol, estriol-3-sulfate, estriol-17-sulfate and tamoxifen in a tamoxifen-resistant cell line (R‐27) derived from MCF‐7 human breast cancer cells.  Eur J Cancer Clin Oncol. 1986;  22 1495-1501
    CrossrefPubMedGoogle Scholar
  • 62 Davidson B J, Gambone J C, Lagasse L D, Castaldo T W, Hammond G L, Siiteri P K, Judd H L. Free estradiol in postmenopausal women with and without endometrial cancer.  J Clin Endocrinol Metab. 1981;  52 404-408
    PubMedGoogle Scholar
  • 63 Vignon F, Terqui M, Westley B, Derocq D, Rochefort H. Effects of plasma estrogen sulfates in mammary cancer cells.  Endocrinology. 1980;  106 1079-1086
    PubMedGoogle Scholar
  • 64 MacIndoe J H. The hydrolysis of estrone sulfate and dehydroepiandrosterone sulfate by MCF‐7 human breast cancer cells.  Endocrinology. 1988;  123 1281-1287
    PubMedGoogle Scholar
  • 65 Pasqualini J R, Maloche C, Maroni M, Chetrite G. Effect of the progestagen promegestone (R-5020) on mRNA of the oestrone sulphatase in the MCF‐7 human mammary cancer cells.  Anticancer Res. 1994;  14 1589-1593
    PubMedGoogle Scholar
  • 66 Utsumi T, Yoshimura N, Takeuchi S, Maruta M, Maeda K, Harada N. Elevated steroid sulfatase expression in breast cancers.  J Steroid Biochem Mol Biol. 2000;  73 141-145
    CrossrefPubMedGoogle Scholar
  • 67 Falany J L, Falany C N. Expression of cytosolic sulfotransferases in normal mammary epithelial cells and breast cancer cell lines.  Cancer Res. 1996;  56 1551-1555
    PubMedGoogle Scholar
  • 68 Falany C N, Wheeler J, Oh T S, Falany J L. Steroid sulfation by expressed human cytosolic sulfotransferases.  J Steroid Biochem Mol Biol. 1994;  48 369-375
    CrossrefPubMedGoogle Scholar
  • 69 Malet C, Gompel A, Yaneva H, Cren H, Fidji N, Mowszowicz I, Kuttenn F, Mauvais-Jarvis P. Estradiol and progesterone receptors in cultured normal human breast epithelial cells and fibroblasts: immunocytochemical studies.  J Clin Endocrinol Metab. 1991;  73 8-17
    PubMedGoogle Scholar
  • 70 Singh A, Purohit A, Duncan L J, Mokbel K, Ghilchik M W, Reed M J. Control of aromatase activity in breast tumours: the role of the immune system.  J Steroid Biochem Mol Biol. 1997;  61 185-192
    CrossrefPubMedGoogle Scholar
  • 71 Reed M J, Owen A M, Lai L C, Coldham N G, Ghilchik M W, Shaikh N A, James V H. In situ oestrone synthesis in normal breast and breast tumour tissues: effect of treatment with 4-hydroxyandrostenedione.  Int J Cancer. 1989;  44 233-237
    PubMedGoogle Scholar
  • 72 Yue W, Wang J P, Hamilton C J, Demers L M, Santen R J. In situ aromatization enhances breast tumor estradiol levels and cellular proliferation.  Cancer Res. 1998;  58 927-932
    PubMedGoogle Scholar
  • 73 Czyzyk A, Szczepanik Z. Diabetes mellitus and cancer.  Eur J Intern Med. 2000;  11 245-252
    PubMedGoogle Scholar
  • 74 Verkasalo P K, Thomas H V, Appleby P N, Davey G K, Key T J. Circulating levels of sex hormones and their relation to risk factors for breast cancer: a cross-sectional study in 1092 pre- and postmenopausal women (United Kingdom).  Cancer Causes Control. 2001;  12 47-59
    CrossrefPubMedGoogle Scholar
  • 75 Matsuzawa Y, Funahashi T, Nakamura T. Molecular mechanism of metabolic syndrome X: contribution of adipocytokines adipocyte-derived bioactive substances.  Ann N Y Acad Sci. 1999;  892 146-154
    CrossrefPubMedGoogle Scholar
  • 76 Scherer P E, Williams S, Fogliano M, Baldini G, Lodish H F. A novel serum protein similar to C1 q, produced exclusively in adipocytes.  J Biol Chem. 1995;  270 26746-26749
    CrossrefPubMedGoogle Scholar
  • 77 Yokota T, Oritani K, Takahashi I, Ishikawa J, Matsuyama A, Ouchi N, Kihara S, Funahashi T, Tenner A J, Tomiyama Y, Matsuzawa Y. Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages.  Blood. 2000;  96 1723-1732
    PubMedGoogle Scholar
  • 78 Arita Y, Kihara S, Ouchi N, Maeda K, Kuriyama H, Okamoto Y, Kumada M, Hotta K, Nishida M, Takahashi M, Nakamura T, Shimomura I, Muraguchi M, Ohmoto Y, Funahashi T, Matsuzawa Y. Adipocyte-derived plasma protein adiponectin acts as a platelet-derived growth factor-BB-binding protein and regulates growth factor-induced common postreceptor signal in vascular smooth muscle cell.  Circulation. 2002;  105 2893-2898
    CrossrefPubMedGoogle Scholar
  • 79 Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K, Mori Y, Ide T, Murakami K, Tsuboyama-Kasaoka N, Ezaki O, Akanuma Y, Gavrilova O, Vinson C, Reitman M L, Kagechika H, Shudo K, Yoda M, Nakano Y, Tobe K, Nagai R, Kimura S, Tomita M, Froguel P, Kadowaki T. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity.  Nat Med. 2001;  7 941-946
    CrossrefPubMedGoogle Scholar
  • 80 Berg A H, Combs T P, Du X, Brownlee M, Scherer P E. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action.  Nat Med. 2001;  7 947-953
    CrossrefPubMedGoogle Scholar
  • 81 Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y, Iwahashi H, Kuriyama H, Ouchi N, Maeda K, Nishida M, Kihara S, Sakai N, Nakajima T, Hasegawa K, Muraguchi M, Ohmoto Y, Nakamura T, Yamashita S, Hanafusa T, Matsuzawa Y. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients.  Arterioscler Thromb Vasc Biol. 2000;  20 1595-1599
    CrossrefPubMedGoogle Scholar
  • 82 Yang W S, Lee W J, Funahashi T, Tanaka S, Matsuzawa Y, Chao C L, Chen C L, Tai T Y, Chuang L M. Plasma adiponectin levels in overweight and obese Asians.  Obes Res. 2002;  10 1104-1110
    CrossrefPubMedGoogle Scholar
  • 83 Mantzoros C, Petridou E, Dessypris N, Chavelas C, Dalamaga M, Alexe D M, Papadiamantis Y, Markopoulos C, Spanos E, Chrousos G, Trichopoulos D. Adiponectin and breast cancer risk.  J Clin Endocrinol Metab. 2004;  89 1102-1107
    CrossrefPubMedGoogle Scholar
  • 84 Miyoshi Y, Funahashi T, Kihara S, Taguchi T, Tamaki Y, Matsuzawa Y, Noguchi S. Association of serum adiponectin levels with breast cancer risk.  Clin Cancer Res. 2003;  9 5699-5704
    PubMedGoogle Scholar
  • 85 Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman J M. Positional cloning of the mouse obese gene and its human homologue.  Nature. 1994;  372 425-432
    CrossrefPubMedGoogle Scholar
  • 86 Sinha M K, Opentanova I, Ohannesian J P, Kolaczynski J W, Heiman M L, Hale J, Becker G W, Bowsher R R, Stephens T W, Caro J F. Evidence of free and bound leptin in human circulation. Studies in lean and obese subjects and during short-term fasting.  J Clin Invest. 1996;  98 1277-1282
    CrossrefPubMedGoogle Scholar
  • 87 McGregor G P, Desaga J F, Ehlenz K, Fischer A, Heese F, Hegele A, Lammer C, Peiser C, Lang R E. Radiommunological measurement of leptin in plasma of obese and diabetic human subjects.  Endocrinology. 1996;  137 1501-1504
    CrossrefPubMedGoogle Scholar
  • 88 Catalano S, Marsico S, Giordano C, Mauro L, Rizza P, Panno M L, Ando S. Leptin enhances, via AP‐1, expression of aromatase in the MCF‐7 cell line.  J Biol Chem. 2003;  278 28668-28676
    CrossrefPubMedGoogle Scholar
  • 89 O'brien S N, Welter B H, Price T M. Presence of leptin in breast cell lines and breast tumors.  Biochem Biophys Res Commun. 1999;  259 695-698
    CrossrefPubMedGoogle Scholar
  • 90 Hu X, Juneja S C, Maihle N J, Cleary M P. Leptin - a growth factor in normal and malignant breast cells and for normal mammary gland development.  J Natl Cancer Inst. 2002;  94 1704-1711
    PubMedGoogle Scholar
  • 91 Cleary M P, Juneja S C, Phillips F C, Hu X, Grande J P, Maihle N J. Leptin receptor-deficient MMTV‐TGF-alpha/Lepr(db)Lepr(db) female mice do not develop oncogene-induced mammary tumors.  Exp Biol Med (Maywood). 2004;  229 182-193
    PubMedGoogle Scholar
  • 92 Tessitore L, Vizio B, Jenkins O, De Stefano I, Ritossa C, Argiles J M, Benedetto C, Mussa A. Leptin expression in colorectal and breast cancer patients.  Int J Mol Med. 2000;  5 421-426
    PubMedGoogle Scholar
  • 93 Mantzoros C S, Bolhke K, Moschos S, Cramer D W. Leptin in relation to carcinoma in situ of the breast: a study of pre-menopausal cases and controls.  Int J Cancer. 1999;  80 523-526
    CrossrefPubMedGoogle Scholar
  • 94 Lind D S, Tuttle T M, Bethke K P, Frank J L, McCrady C W, Bear H D. Expansion and tumour specific cytokine secretion of bryostatin-activated T-cells from cryopreserved axillary lymph nodes of breast cancer patients.  Surg Oncol. 1993;  2 273-82
    PubMedGoogle Scholar
  • 95 Rozen F, Zhang J, Pollak M. Antiproliferative action of tumor necrosis factor-alpha on MCF‐7 breast cancer cells is associated with increased insulin-like growth factor binding protein-3 accumulation.  Int J Oncol. 1998;  13 865-869
    PubMedGoogle Scholar
  • 96 Pagliacci M C, Fumi G, Migliorati G, Grignani F, Riccardi C, Nicoletti I. Cytostatic and cytotoxic effects of tumor necrosis factor alpha on MCF‐7 human breast tumor cells are differently inhibited by glucocorticoid hormones.  Lymphokine Cytokine Res. 1993;  12 439-447
    PubMedGoogle Scholar
  • 97 Purohit A, Reed M J. Regulation of estrogen synthesis in postmenopausal women.  Steroids. 2002;  67 979-983
    CrossrefPubMedGoogle Scholar
  • 98 Fajardo L F, Kwan H H, Kowalski J, Prionas S D, Allison A C. Dual role of tumor necrosis factor-alpha in angiogenesis.  Am J Pathol. 1992;  140 539-544
    PubMedGoogle Scholar
  • 99 Weitsman G E, Ravid A, Liberman U A, Koren R. Vitamin D enhances caspase-dependent and ‐independent TNFalpha-induced breast cancer cell death: The role of reactive oxygen species and mitochondria.  Int J Cancer. 2003;  106 178-186
    CrossrefPubMedGoogle Scholar
  • 100 Lee P P, Hwang J J, Murphy G, Ip M M. Functional significance of MMP‐9 in tumor necrosis factor-induced proliferation and branching morphogenesis of mammary epithelial cells.  Endocrinology. 2000;  141 3764-3773
    CrossrefPubMedGoogle Scholar
  • 101 Leek R D, Landers R, Fox S B, Ng F, Harris A L, Lewis C E. Association of tumour necrosis factor alpha and its receptors with thymidine phosphorylase expression in invasive breast carcinoma.  Br J Cancer. 1998;  77 2246-2251
    PubMedGoogle Scholar
  • 102 Meisser A, Cameo P, Islami D, Campana A, Bischof P. Effects of interleukin-6 (IL‐6) on cytotrophoblastic cells.  Mol Hum Reprod. 1999;  5 1055-1058
    CrossrefPubMedGoogle Scholar
  • 103 Salgado R, Junius S, Benoy I, Van Dam P, Vermeulen P, Van Marck E, Huget P, Dirix L Y. Circulating interleukin-6 predicts survival in patients with metastatic breast cancer.  Int J Cancer. 2003;  103 642-646
    CrossrefPubMedGoogle Scholar
  • 104 DECODE Study Group . Age- and sex-specific prevalences of diabetes and impaired glucose regulation in 13 European cohorts.  Diabetes Care. 2003;  26 61-69
    CrossrefPubMedGoogle Scholar
  • 105 Weiderpass E, Gridley G, Persson I, Nyren O, Ekbom A, Adami H O. Risk of endometrial and breast cancer in patients with diabetes mellitus.  Int J Cancer. 1997;  71 360-363
    CrossrefPubMedGoogle Scholar
  • 106 Milazzo G, Giorgino F, Damante G, Sung C, Stampfer M R, Vigneri R, Goldfine I D, Belfiore A. Insulin receptor expression and function in human breast cancer cell lines.  Cancer Res. 1992;  52 3924-3930
    PubMedGoogle Scholar
  • 107 Yenush L, White M F. The IRS-signalling system during insulin and cytokine action.  Bioessays. 1997;  19 491-500
    CrossrefPubMedGoogle Scholar
  • 108 Jackson J G, White M F, Yee D. Insulin receptor substrate-1 is the predominant signaling molecule activated by insulin-like growth factor-I, insulin, and interleukin-4 in estrogen receptor-positive human breast cancer cells.  J Biol Chem. 1998;  273 9994-10003
    CrossrefPubMedGoogle Scholar
  • 109 Lai A, Sarcevic B, Prall O W, Sutherland R L. Insulin/insulin-like growth factor-I and estrogen cooperate to stimulate cyclin E-Cdk2 activation and cell Cycle progression in MCF‐7 breast cancer cells through differential regulation of cyclin E and p 21(WAF1/Cip1).  J Biol Chem. 2001;  276 25823-25833
    CrossrefPubMedGoogle Scholar
  • 110 Goodwin P J, Ennis M, Pritchard K I, Trudeau M E, Koo J, Madarnas Y, Hartwick W, Hoffman B, Hood N. Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study.  J Clin Oncol. 2002;  20 42-51
    CrossrefPubMedGoogle Scholar
  • 111 Godden J, Leake R, Kerr D J. The response of breast cancer cells to steroid and peptide growth factors.  Anticancer Res. 1992;  12 1683-1688
    PubMedGoogle Scholar
  • 112 Chappell J, Leitner J W, Solomon S, Golovchenko I, Goalstone M L, Draznin B. Effect of insulin on cell cycle progression in MCF‐7 breast cancer cells. Direct and potentiating influence.  J Biol Chem. 2001;  276 38023-38028
    PubMedGoogle Scholar
  • 113 Sepp-Lorenzino L, Rosen N, Lebwohl D E. Insulin and insulin-like growth factor signaling are defective in the MDA MB‐468 human breast cancer cell line.  Cell Growth Differ. 1994;  5 1077-1083
    PubMedGoogle Scholar
  • 114 Wolf I, Seger R. The mitogen-activated protein kinase signaling cascade: from bench to bedside.  Isr Med Assoc J. 2002;  4 641-647
    PubMedGoogle Scholar
  • 115 Papa V, Reese C C, Brunetti A, Vigneri R, Siiteri P K, Goldfine I D. Progestins increase insulin receptor content and insulin stimulation of growth in human breast carcinoma cells.  Cancer Res. 1990;  50 7858-7862
    PubMedGoogle Scholar
  • 116 Webster N J, Resnik J L, Reichart D B, Strauss B, Haas M, Seely B L. Repression of the insulin receptor promoter by the tumor suppressor gene product p 53: a possible mechanism for receptor overexpression in breast cancer.  Cancer Res. 1996;  56 2781-2788
    PubMedGoogle Scholar
  • 117 Frittitta L, Cerrato A, Sacco M G, Weidner N, Goldfine I D, Vigneri R. The insulin receptor content is increased in breast cancers initiated by three different oncogenes in transgenic mice.  Breast Cancer Res Treat. 1997;  45 141-147
    CrossrefPubMedGoogle Scholar
  • 118 Frittitta L, Vigneri R, Stampfer M R, Goldfine I D. Insulin receptor overexpression in 184B5 human mammary epithelial cells induces a ligand-dependent transformed phenotype.  J Cell Biochem. 1995;  57 666-669
    CrossrefPubMedGoogle Scholar
  • 119 Papa V, Pezzino V, Costantino A, Belfiore A, Giuffrida D, Frittitta L, Vannelli G B, Brand R, Goldfine I D, Vigneri R. Elevated insulin receptor content in human breast cancer.  J Clin Invest. 1990;  86 1503-1510
    CrossrefPubMedGoogle Scholar
  • 120 Renehan A G, Zwahlen M, Minder C, O'Dwyer S T, Shalet S M, Egger M. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis.  Lancet. 2004;  363 1346-1353
    CrossrefPubMedGoogle Scholar
  • 121 Rubin R, Baserga R. Insulin-like growth factor-I receptor. Its role in cell proliferation, apoptosis, and tumorigenicity.  Lab Invest. 1995;  73 311-331
    PubMedGoogle Scholar
  • 122 Takahashi T, Ohmichi M, Kawagoe J, Ohshima C, Doshida M, Ohta T, Saitoh M, Mori-Abe A, Du B, Igarashi H, Takahashi K, Kurachi H. Growth factors change nuclear distribution of estrogen receptor-{alpha} via MAP kinase or PI3 kinase cascade in a human breast cancer cell line.  Endocrinology. 2005;  146 4082-4089
    CrossrefPubMedGoogle Scholar
  • 123 Clemmons D R, Underwood L E. Nutritional regulation of IGF‐I and IGF binding proteins.  Annu Rev Nutr. 1991;  11 393-412
    CrossrefPubMedGoogle Scholar
  • 124 Hankinson S E, Willett W C, Colditz G A, Hunter D J, Michaud D S, Deroo B, Rosner B, Speizer F E, Pollak M. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer.  Lancet. 1998;  351 1393-1396
    CrossrefPubMedGoogle Scholar
  • 125 Krajcik R A, Borofsky N D, Massardo S, Orentreich N. Insulin-like growth factor I (IGF‐I), IGF-binding proteins, and breast cancer.  Cancer Epidemiol Biomarkers Prev. 2002;  11 1566-1573
    PubMedGoogle Scholar
  • 126 Siddle K, Urso B, Niesler C A, Cope D L, Molina L, Surinya K H, Soos M A. Specificity in ligand binding and intracellular signalling by insulin and insulin-like growth factor receptors.  Biochem Soc Trans. 2001;  29(Pt 4) 513-525
    CrossrefPubMedGoogle Scholar
  • 127 Bergh C, Carlsson B, Olsson J H, Selleskog U, Hillensjo T. Regulation of androgen production in cultured human thecal cells by insulin-like growth factor I and insulin.  Fertil Steril. 1993;  59 323-331
    PubMedGoogle Scholar
  • 128 Fottner C, Engelhardt D, Weber M M. Regulation of steroidogenesis by insulin-like growth factors (IGFs) in adult human adrenocortical cells: IGF‐I and, more potently, IGF‐II preferentially enhance androgen biosynthesis through interaction with the IGF‐I receptor and IGF-binding proteins.  J Endocrinol. 1998;  158 409-417
    CrossrefPubMedGoogle Scholar
  • 129 Fay M P, Freedman L S, Clifford C K, Midthune D N. Effect of different types and amounts of fat on the development of mammary tumors in rodents: a review.  Cancer Res. 1997;  57 3979-3988
    PubMedGoogle Scholar
  • 130 Rose D P. Effects of dietary fatty acids on breast and prostate cancers: evidence from in vitro experiments and animal studies.  Am J Clin Nutr. 1997;  66 1513S-1522S
    PubMedGoogle Scholar
  • 131 Hardy S, Langelier Y, Prentki M. Oleate activates phosphatidylinositol 3-kinase and promotes proliferation and reduces apoptosis of MDA-MB-231 breast cancer cells, whereas palmitate has opposite effects.  Cancer Res. 2000;  60 6353-6358
    PubMedGoogle Scholar
  • 132 Kaplan D R, Whitman M, Schaffhausen B, Pallas D C, White M, Cantley L, Roberts T M. Common elements in growth factor stimulation and oncogenic transformation: 85 kd phosphoprotein and phosphatidylinositol kinase activity.  Cell. 1987;  50 1021-1029
    CrossrefPubMedGoogle Scholar
  • 133 Hardy S, El-Assaad W, Przybytkowski E, Joly E, Prentki M, Langelier Y. Saturated fatty acid-induced apoptosis in MDA‐MB‐231 breast cancer cells. A role for cardiolipin.  J Biol Chem. 2003;  278 31861-31870
    CrossrefPubMedGoogle Scholar
  • 134 Choi S, Swanson J M. Interaction of cytochrome c with cardiolipin: an infrared spectroscopic study.  Biophys Chem. 1995;  54 271-278
    CrossrefPubMedGoogle Scholar
  • 135 Pardoll D. T cells and tumours.  Nature. 2001;  411 1010-1012
    PubMedGoogle Scholar
  • 136 Richieri G V, Mescher M F, Kleinfeld A M. Short term exposure to cis unsaturated free fatty acids inhibits degranulation of cytotoxic T lymphocytes.  J Immunol. 1990;  144 671-677
    PubMedGoogle Scholar
  • 137 Kleinfeld A M, Okada C. Free fatty acid release from human breast cancer tissue inhibits cytotoxic T lymphocyte-mediated killing.  J Lipid Res. 2005;  46 1983-1990
    PubMedGoogle Scholar
  • 138 El-Sohemy A, Archer M C. Inhibition of N-methyl-N-nitrosourea- and 7,12-dimethylbenz[a] anthracene-induced rat mammary tumorigenesis by dietary cholesterol is independent of Ha-Ras mutations.  Carcinogenesis. 2000;  21 827-831
    CrossrefPubMedGoogle Scholar
  • 139 Bennis F, Favre G, Le Gaillard F, Soula G. Importance of mevalonate-derived products in the control of HMG‐CoA reductase activity and growth of human lung adenocarcinoma cell line A549.  Int J Cancer. 1993;  55 640-645
    PubMedGoogle Scholar
  • 140 Kawata S, Takaishi K, Nagase T, Ito N, Matsuda Y, Tamura S, Matsuzawa Y, Tarui S. Increase in the active form of 3-hydroxy-3-methylglutaryl coenzyme A reductase in human hepatocellular carcinoma: possible mechanism for alteration of cholesterol biosynthesis.  Cancer Res. 1990;  50 3270-3273
    PubMedGoogle Scholar
  • 141 Quesney-Huneeus V, Wiley M H, Siperstein M D. Essential role for mevalonate synthesis in DNA replication.  Proc Natl Acad Sci U S A. 1979;  76 5056-5060
    CrossrefPubMedGoogle Scholar
  • 142 Duncan R E, El-Sohemy A, Archer M C. Mevalonate promotes the growth of tumors derived from human cancer cells in vivo and stimulates proliferation in vitro with enhanced cyclin-dependent kinase-2 activity.  J Biol Chem. 2004;  279 33079-33084
    CrossrefPubMedGoogle Scholar
  • 143 Keyomarsi K, Sandoval L, Band V, Pardee A B. Synchronization of tumor and normal cells from G1 to multiple cell cycles by lovastatin.  Cancer Res. 1991;  51 3602-3609
    PubMedGoogle Scholar
  • 144 Melhem M F, Gabriel H F, Eskander E D, Rao K N. Cholestyramine promotes 7,12-dimethylbenzanthracene induced mammary cancer in Wistar rats.  Br J Cancer. 1987;  56 45-48
    PubMedGoogle Scholar
  • 145 Rao K N, Melhem M F, Gabriel H F, Eskander E D, Kazanecki M E, Amenta J S. Lipid composition and de novo cholesterogenesis in normal and neoplastic rat mammary tissues.  J Natl Cancer Inst. 1988;  80 1248-1253
    PubMedGoogle Scholar
  • 146 Rotheneder M, Kostner G M. Effects of low- and high-density lipoproteins on the proliferation of human breast cancer cells in vitro: differences between hormone-dependent and hormone-independent cell lines.  Int J Cancer. 1989;  43 875-879
    PubMedGoogle Scholar
  • 147 Cao W M, Murao K, Imachi H, Yu X, Abe H, Yamauchi A, Niimi M, Miyauchi A, Wong N C, Ishida T. A mutant high-density lipoprotein receptor inhibits proliferation of human breast cancer cells.  Cancer Res. 2004;  64 1515-1521
    CrossrefPubMedGoogle Scholar
  • 148 Gregorio D I, Emrich L J, Graham S, Marshall J R, Nemoto T. Dietary fat consumption and survival among women with breast cancer.  J Natl Cancer Inst. 1985;  75 37-41
    PubMedGoogle Scholar
  • 149 Zhang S, Folsom A R, Sellers T A, Kushi L H, Potter J D. Better breast cancer survival for postmenopausal women who are less overweight and eat less fat. The Iowa Women's Health Study.  Cancer. 1995;  76 275-283
    PubMedGoogle Scholar
  • 150 Kyogoku S, Hirohata T, Nomura Y, Shigematsu T, Takeshita S, Hirohata I. Diet and prognosis of breast cancer.  Nutr Cancer. 1992;  17 271-277
    PubMedGoogle Scholar
  • 151 Kaaks R. Lundin E, Manjer J, Rinaldi S, Biessy C, Soderberg S, Lenner P, Janzon L, Riboli E, Berglund G, Hallmans G. Prospective study of IGF‐I, IGF- binding proteins, and breast cancer risk, in Northern and Southern Sweden.  Cancer Causes Control. 2002;  13 307-316
    CrossrefPubMedGoogle Scholar
  • 152 Schairer C, Hill D, Sturgeon S, Fears T, Pollak M, Mies C, Ziegler R, Hoover R, Sherman M. Serum concentration of IGF‐I, IGFBP‐3 and C-peptide and risk of hyperplasia and cancer of the breast in postmenopausal women.  Int J Cancer. 2004;  108 773-779
    CrossrefPubMedGoogle Scholar
  • 153 Dale K M, Coleman C I, Henyan N N, Kluger J, White C M. Statins and cancer risk: a meta-analysis.  JAMA. 2006;  295 74-80
    CrossrefPubMedGoogle Scholar
  • 154 Zhu B T, Connery A H. Is 2-methoxyestradiol an endogenous metabolite that inhibits mammary carcinogenesis?.  Cancer Res. 1998;  58 2269-2277
    PubMedGoogle Scholar
  • 155 Seeger H, Wallwiener D, Kraemer E, Mueck A O. Comparison of possible carcinogenic estradiol metabolites: Effects on proliferation, apoptosis and metastasis of human breast cancer cells.  Maturitas. 2006;  54 (1) 72-77
    CrossrefPubMedGoogle Scholar
  • 156 Seeger H, Wallwiener D, Mueck A O. Different effects of estradiol and various antiestrogens on TNF-alpha-induced changes of biochemical markers for growth and invasion of human breast cancer cells.  Life Sci. 2006;  78 (13) 1464-1468
    CrossrefPubMedGoogle Scholar

Prof. Dr. O. Ortmann

Klinik für Frauenheilkunde und Geburtshilfe
Universität Regensburg

Landshuter Str. 65

93053 Regensburg

eMail: gynaekologie@caritasstjosef.de

      >